Drug Profile
Influenza virus strain H5N1 clade 1 vaccine - Sanofi
Alternative Names: AF 03; Avian influenza (bird flu) virus vaccine - Sanofi/NIAID; Emerflu; H5N1 influenza vaccine - sanofi; H5N1 split antigen influenza vaccine Alum adjuvanted - sanofi; Low-dose H5N1 vaccine - sanofi; Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) A/Vietnam/1194/2004 (NIBRG-14) - sanofi; Pandemic influenza vaccine - sanofiLatest Information Update: 04 Apr 2022
Price :
$50
*
At a glance
- Originator sanofi pasteur
- Developer Sanofi; sanofi pasteur
- Class Influenza A virus H5N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Influenza A virus H5N1 subtype
Most Recent Events
- 29 Nov 2017 Sanofi Pasteur's influenza virus strain H5N1 clade 1 vaccine is registered in USA and Australia and will not be sold commercially
- 20 Mar 2015 The vaccine is approved in USA and Australia for Influenza A virus H5n1 subtype (Prevention)
- 20 Mar 2015 No recent reports on development identified - Phase-II for Influenza-A virus H5N1 subtype (In children, Prevention) in Thailand (IM)